Form D · Biotechnology
Angiocrine Bioscience, Inc.
San Diego, CA · CIK 0001569052
Offering snapshot reported Sep 5, 2025 · SEC filing
- Reported sold
- $2.1M Offering amount: $3M
- Investors reported
- 16 Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Aug 21, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 5, 2025 | Initial | $2,100,000 | No comparison | 16 | SEC filing |
| Oct 15, 2021 | Initial | $58,121,796 | No comparison | 78 | SEC filing |
| Mar 13, 2013 | Initial | $3,999,999 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-556712
Source: Form D, filed Sep 5, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Marc Cohen | Director |
| Brad Daniel | Director |
| Claude Geoffrey Davis, Ph.D. | Director, Executive |
| Paul W Finnegan | Director, Executive |
| John R Jaskowiak | Executive |
| Jeff Jonas | Director |
| John Klacking, Ph.D. | Director, Executive |
| John T Lomoro | Executive |
| Rick Murdock | Director |
| David Parkinson | Director |
| Jeffrey L Port | Director |
| Jeffrey L. Port, M.D. | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
11585 Sorrento Valley Rd, Ste 109
San Diego, CA, 92121
San Diego, CA, 92121